Literature DB >> 31404445

Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.

Mustafa Al-Kawaaz1, Teresa Sanchez1,2, Michael J Kluk1.   

Abstract

BACKGROUND: Aggressive, mature B-cell lymphomas include Burkitt Lymphoma (BL), High Grade B Cell Lymphomas (HGBL) (eg, Double-Hit B cell lymphomas (HGBL-DH: HGBL with MYC and BCL2 and/or BCL6 translocations)), HGBL, Not Otherwise Specified (HGBL, NOS) and Diffuse Large B Cell Lymphoma (DLBCL). Overlapping morphologic and immunohistochemical features of these lymphomas pose diagnostic challenges in some cases, and better understanding of potential diagnostic biomarkers and possible therapeutic targets is needed. Sphingosine 1 Phosphate Receptors (S1PR1-5) are G-protein coupled receptors that bind S1P and influence migration and survival in multiple cell types, including lymphocytes. S1PRs are emerging as biomarkers in B cell biology and interaction between S1PR pathways and STAT3 or FOXP1 has been reported in DLBCL. AIM AND METHODS: Our aim was to extend the understanding of S1PR1, STAT3 and S1PR2, FOXP1 expression beyond DLBCL, into additional aggressive, mature B cell lymphomas using immunohistochemical expression analysis of human tissue samples.
RESULTS: S1PR1 and S1PR2 showed different expression patterns in mantle zones and follicle centers in reactive lymphoid tissue. BL showed a unique expression pattern compared to HGBL and DLBCL. Additionally, S1PR1 and S1PR2 expression were typically mutually exclusive and were expressed in a low proportion of cases (frequently HGBL involving extranodal sites). FOXP1 was expressed in a high proportion of various case types and pSTAT3 was detected in a significant proportion of HGBL and DLBCL.
CONCLUSIONS: These findings provide further evidence that S1PR1, pSTAT3, S1PR2 and FOXP1 play a role in a subset of aggressive, mature B cell lymphomas.

Entities:  

Keywords:  FOXP1; S1P; S1PR; Sphingosine-1-Phosphate; lymphoma; pSTAT3

Year:  2019        PMID: 31404445      PMCID: PMC6688509          DOI: 10.1007/s12308-019-00354-y

Source DB:  PubMed          Journal:  J Hematop        ISSN: 1865-5785            Impact factor:   0.196


  28 in total

1.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

2.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Authors:  Anna Yemelyanova; Russell Vang; Malti Kshirsagar; Dan Lu; Morgan A Marks; Ie Ming Shih; Robert J Kurman
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

3.  Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.

Authors:  Giorgio Cattoretti; Jonathan Mandelbaum; Nancy Lee; Alicia H Chaves; Ashley M Mahler; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci; A John MacLennan
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

4.  Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma.

Authors:  Hirotake Nishimura; Takashi Akiyama; Yasumasa Monobe; Kiminori Matsubara; Yasuyuki Igarashi; Masafumi Abe; Takashi Sugihara; Yoshito Sadahira
Journal:  Mod Pathol       Date:  2010-01-15       Impact factor: 7.842

5.  Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

Authors:  Lloyd T Lam; George Wright; R Eric Davis; Georg Lenz; Pedro Farinha; Lenny Dang; John W Chan; Andreas Rosenwald; Randy D Gascoyne; Louis M Staudt
Journal:  Blood       Date:  2007-12-26       Impact factor: 22.113

6.  S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.

Authors:  Yong Liu; Jiehui Deng; Lin Wang; Heehyoung Lee; Brian Armstrong; Anna Scuto; Claudia Kowolik; Lawrence M Weiss; Stephen Forman; Hua Yu
Journal:  Blood       Date:  2012-06-28       Impact factor: 22.113

7.  Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration.

Authors:  Michael J Kluk; Kieran P Ryan; Bonnie Wang; Guoqi Zhang; Scott J Rodig; Teresa Sanchez
Journal:  Lab Invest       Date:  2013-02-18       Impact factor: 5.662

8.  STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.

Authors:  Heehyoung Lee; Jiehui Deng; Maciej Kujawski; Chunmei Yang; Yong Liu; Andreas Herrmann; Marcin Kortylewski; David Horne; George Somlo; Stephen Forman; Richard Jove; Hua Yu
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

9.  The sphingosine 1-phosphate receptor S1P₂ maintains the homeostasis of germinal center B cells and promotes niche confinement.

Authors:  Jesse A Green; Kazuhiro Suzuki; Bryan Cho; L David Willison; Daniel Palmer; Christopher D C Allen; Timothy H Schmidt; Ying Xu; Richard L Proia; Shaun R Coughlin; Jason G Cyster
Journal:  Nat Immunol       Date:  2011-06-05       Impact factor: 25.606

10.  High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.

Authors:  Z L Wu; Y Q Song; Y F Shi; J Zhu
Journal:  J Hematol Oncol       Date:  2011-08-01       Impact factor: 17.388

View more
  2 in total

Review 1.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

Review 2.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.